Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported
Outcomes-16-Week Results from a Placebo-controlled Phase 2
Study in Patients with Active Psoriatic Arthritis

a 2022

Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

TAYLOR, Peter; Frank BEHRENS; Philip J. MEASE; Dieter WETZEL; Paul PELOSO et al.

Základní údaje

Originální název

Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

Autoři

Vydání

2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.300

Kód RIV

RIV/00216224:14160/22:00128083

Organizační jednotka

Farmaceutická fakulta

ISSN

UT WoS

000877386500199

Klíčová slova anglicky

Izokibep; IL-17A inhibitor; patient outcomes; psoriatic arthriris; clinical trial

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam

Změněno: 19. 1. 2023 09:26, JUDr. Sabina Gajdzioková

Anotace

V originále

Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a key driver of the PsA disease process, which greatly impacts patients’ physical function, vitality, social participation, mood, and quality of life. Here, we report 16-week results of izokibep on patient-reported outcomes (PROs) in adult patients with active PsA.

Citovat

TAYLOR, Peter; Frank BEHRENS; Philip J. MEASE; Dieter WETZEL; Paul PELOSO; Nicolai BRUN; Brian WIENS; Jan BRANDTJUERGENS; Edit DRESCHER; Eva DOKOUPILOVÁ; Anna ROWINSKA-OSUCH; Nadia Abdel-Kader MARTIN a Kurt DE VLAM. Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis. 2022. ISSN 2326-5191.

@proceedings{2247558,
   author = {Taylor, Peter and Behrens, Frank and Mease, Philip J. and Wetzel, Dieter and Peloso, Paul and Brun, Nicolai and Wiens, Brian and Brandtjuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and Martin, Nadia AbdelandKader and de Vlam, Kurt},
   keywords = {Izokibep; IL-17A inhibitor; patient outcomes; psoriatic arthriris; clinical trial},
   language = {eng},
   title = {Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis},
   url = {https://acrabstracts.org/abstract/izokibep-a-novel-il-17a-inhibitor-improves-patient-reported-outcomes-16-week-results-from-a-placebo-controlled-phase-2-study-in-patients-with-active-psoriatic-arthritis/},
   year = {2022}
}

TY  - CONF
ID  - 2247558
AU  - Taylor, Peter - Behrens, Frank - Mease, Philip J. - Wetzel, Dieter - Peloso, Paul - Brun, Nicolai - Wiens, Brian - Brandtjuergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Martin, Nadia Abdel-Kader - de Vlam, Kurt
PY  - 2022
TI  - Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
KW  - Izokibep
KW  - IL-17A inhibitor
KW  - patient outcomes
KW  - psoriatic arthriris
KW  - clinical trial
UR  - https://acrabstracts.org/abstract/izokibep-a-novel-il-17a-inhibitor-improves-patient-reported-outcomes-16-week-results-from-a-placebo-controlled-phase-2-study-in-patients-with-active-psoriatic-arthritis/
N2  - Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a key driver of the PsA disease process, which greatly impacts patients’ physical function, vitality, social participation, mood, and quality of life. Here, we report 16-week results of izokibep on patient-reported outcomes (PROs) in adult patients with active PsA.
ER  -

TAYLOR, Peter; Frank BEHRENS; Philip J. MEASE; Dieter WETZEL; Paul PELOSO; Nicolai BRUN; Brian WIENS; Jan BRANDTJUERGENS; Edit DRESCHER; Eva DOKOUPILOVÁ; Anna ROWINSKA-OSUCH; Nadia Abdel-Kader MARTIN a Kurt DE VLAM. \textit{Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis}. 2022. ISSN~2326-5191.

Přehled o publikaci